NASDAQ:CPIX Cumberland Pharmaceuticals (CPIX) Stock Price, News & Analysis $6.57 +0.77 (+13.28%) Closing price 04:00 PM EasternExtended Trading$6.59 +0.02 (+0.30%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CPIX alerts:Sign Up Key Stats Today's Range$5.32▼$6.7550-Day Range$4.22▼$8.4952-Week Range$1.88▼$9.28Volume163,212 shsAverage Volume240,467 shsMarket Capitalization$98.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company based in Nashville, Tennessee. Founded in 1999, the company develops, acquires and commercializes branded prescription medicines, with a focus on products used in hospital and other acute-care settings as well as treatments for chronic conditions. Its marketed products include Acetadote, an intravenous treatment for acetaminophen overdose; Caldolor, an intravenous ibuprofen product used to treat pain and fever; and Kristalose, a prescription treatment for constipation. Cumberland also markets products for other conditions, including Vaprisol for certain hospitalized patients with low blood sodium and Vibativ, an antibacterial medicine. Cumberland sells its products in the United States and uses distribution partners for select international markets. Founder A.J. Kazimi has served as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Cumberland Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreCPIX MarketRank™: 1.40347361389 of 5 starsCumberland Pharmaceuticals scored higher than 28% of companies evaluated by MarketBeat, and ranked 1539th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCumberland Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCumberland Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Cumberland Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is 1.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is 1.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.66.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.46% of the float of Cumberland Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCumberland Pharmaceuticals has a short interest ratio ("days to cover") of 1.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cumberland Pharmaceuticals has recently decreased by 10.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.25 News SentimentCumberland Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cumberland Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for CPIX on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.51% of the stock of Cumberland Pharmaceuticals is held by institutions.Read more about Cumberland Pharmaceuticals' insider trading history. Receive CPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPIX Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cumberland Pharmaceuticals Inc. - CPIXNovember 17 at 5:31 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cumberland Pharmaceuticals Inc. - CPIXNovember 12, 2026 | prnewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 18 at 1:00 AM | Behind the Markets (Ad)Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Break Above 200 Day Moving Average - What's Next?November 12, 2026 | americanbankingnews.comCumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMDNovember 10, 2026 | seekingalpha.comCUMBERLAND PHARMACEUTICALS REPORTS Q3 2026 FINANCIAL RESULTS & COMPANY UPDATENovember 10, 2026 | prnewswire.comAnalyzing Cumberland Pharmaceuticals (NASDAQ:CPIX) and Scilex (NASDAQ:SCLX)November 8, 2026 | americanbankingnews.comCUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTSNovember 3, 2026 | prnewswire.comSee More Headlines CPIX Stock Analysis - Frequently Asked Questions How have CPIX shares performed this year? Cumberland Pharmaceuticals' stock was trading at $3.98 at the start of the year. Since then, CPIX stock has increased by 65.1% and is now trading at $6.57. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) issued its earnings results on Tuesday, August, 4th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.07. The specialty pharmaceutical company earned $166.46 thousand during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a net margin of 274.38% and a negative trailing twelve-month return on equity of 19.50%. Read the conference call transcript. Who are Cumberland Pharmaceuticals' major shareholders? Cumberland Pharmaceuticals' top institutional shareholders include Diversified Trust Co (4.67%), State Street Corp (0.27%), Empowered Funds LLC (0.16%) and Lantern Wealth Advisors LLC (0.09%). View institutional ownership trends. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cumberland Pharmaceuticals investors own include NVIDIA (NVDA), onsemi (ON), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), PayPal (PYPL) and Johnson & Johnson (JNJ). Company Calendar Last Earnings8/04/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CPIX's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CPIX CIK1087294 Webwww.cumberlandpharma.com Phone(615) 255-0068Fax615-255-0094Employees93Year Founded1999Profitability EPS (Trailing Twelve Months)$4.49 Trailing P/E Ratio1.46 Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.84 million Net Margins274.38% Pretax Margin-22.69% Return on Equity-19.50% Return on Assets-8.12% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio0.96 Sales & Book Value Annual Sales$44.52 million Price / Sales2.21 Cash Flow$0.46 per share Price / Cash Flow14.21 Book Value$4.81 per share Price / Book1.37Miscellaneous Outstanding Shares15,000,000Free Float8,680,000Market Cap$98.55 million OptionableOptionable Beta0.16 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:CPIX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.